Institute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
World-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov University, Moscow, Russia.
PLoS One. 2022 Jun 3;17(6):e0264903. doi: 10.1371/journal.pone.0264903. eCollection 2022.
Cardiovascular diseases associated with high cholesterol (hypercholesterolemia) and low-density lipoproteins (LDL) levels are significant contributors to total mortality in developing and developed countries. Mathematical modeling of LDL metabolism is an important step in the development of drugs for hypercholesterolemia. The aim of this work was to develop and to analyze an integrated mathematical model of cholesterol metabolism in liver cells and its interaction with two types of drugs, statins and PCSK9 inhibitors. The model consisted of 21 ordinary differential equations (ODE) describing cholesterol biosynthesis and lipoprotein endocytosis in liver cells in vitro. The model was tested for its ability to mimic known biochemical effects of familial hypercholesterolemia, statin therapy, and PCSK9 inhibitors. The model qualitatively reproduced the well-known biology of cholesterol regulation, which confirms its potential for minimizing cellular research in initial testing of new drugs for cardiology.
与高胆固醇(高胆固醇血症)和低密度脂蛋白(LDL)水平相关的心血管疾病是发展中国家和发达国家总死亡率的重要原因。LDL 代谢的数学建模是开发高胆固醇血症药物的重要步骤。本工作的目的是开发和分析肝细胞胆固醇代谢及其与两种药物(他汀类药物和 PCSK9 抑制剂)相互作用的综合数学模型。该模型由 21 个常微分方程(ODE)组成,用于描述体外肝细胞中胆固醇的生物合成和脂蛋白内吞作用。该模型经过测试,能够模拟家族性高胆固醇血症、他汀类药物治疗和 PCSK9 抑制剂的已知生化作用。该模型定性地再现了胆固醇调节的著名生物学,这证实了其在最初测试心脏病学新药时减少细胞研究的潜力。